Dova Pharmaceuticals is a clinical-stage pharmaceutical company focused on acquiring, developing, and marketing treatments for thrombocytopenia, a disorder characterized by a low blood platelet count. Its major drug candidate, Avatrombopag, is an orally administered thrombopoietin receptor agonist.